Cerus (NASDAQ: CERS) — Company Overview, News & Financial Data
Cerus develops innovative blood transfusion solutions to enhance blood safety, focused on the Intercept Blood System.
Cerus
Cerus (NASDAQ:CERS) is a biomedical products company engaged in the development and provision of innovative blood transfusion solutions. Their main focus is on enhancing blood safety through their Intercept Blood System, designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites present in donated blood. The company is solely listed on the NASDAQ stock exchange under the ticker symbol CERS. Cerus is dedicated to protecting public health and improving patient care by addressing critical needs in blood safety. Their objectives include expanding the adoption of the Intercept Blood System globally, investing in research and development to extend their product offerings, and exploring new opportunities to leverage their pathogen inactivation technology across different medical applications.
Snapshot
Operations
Products and/or services of Cerus
- INTERCEPT Blood System for platelets and plasma, designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens.
- INTERCEPT Blood System for red blood cells, aimed at enhancing the safety of red blood cell transfusions by inactivating pathogens.
- Pathogen Reduction Technology (PRT) services, offering solutions to blood centers and hospitals for implementing pathogen reduction strategies in their blood supply.
- Collaboration and partnership services with blood centers, healthcare institutions, and governments worldwide to promote the adoption of pathogen reduction technologies.
- Research and development in next-generation pathogen reduction technologies, focusing on innovations to improve blood safety and availability.
- Educational programs and resources for healthcare professionals, aimed at increasing awareness and knowledge about the importance of blood safety and pathogen reduction.
Cerus executive team
- William M. GreenmanExecutive Chairman of the Board
- Vivek K. JayaramanCEO, President & Director
- Kevin D. GreenVP of Finance & CFO
- Chrystal N. JensenChief Legal Officer, General Counsel & Secretary
- Richard J. BenjaminChief Medical Officer
- Bianca VosVice President of Administration
- Timothy J. LeeHead of Investor Relation
- Lainie CortenVice President of Global Marketing
- Nina MuftiSenior VP of Research & Development
- Christian BoutemyVP & MD of Cerus International